{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:27:10Z","timestamp":1793053630778,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>What are the chances of obtaining a healthy transferable cleavage-stage embryo according to the number of mature oocytes in fragile X mental retardation 1 (FMR1)-mutated or premutated females undergoing preimplantation genetic testing (PGT)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>In our population, a cycle with seven or more mature oocytes has an 83% chance of obtaining one or more healthy embryos.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>PGT may be an option to achieve a pregnancy with a healthy baby for FMR1 mutation carriers. In addition, FMR1 premutation is associated with a higher risk of diminished ovarian reserve and premature ovarian failure. The number of metaphase II (MII) oocytes needed to allow the transfer of a healthy embryo following PGT has never been investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>The study is a monocentric retrospective observational study carried out from January 2006 to January 2020 that is associated with a case-control study and that analyzes 38 FMR1 mutation female carriers who are candidates for PGT; 16 carried the FMR1 premutation and 22 had the full FMR1 mutation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>A total of 95 controlled ovarian stimulation (COS) cycles for PGT for fragile X syndrome were analyzed, 49 in premutated patients and 46 in fully mutated women. Only patients aged \u226438\u2009years with anti-M\u00fcllerian hormone (AMH) &amp;gt;1\u2009ng\/ml and antral follicle count (AFC) &amp;gt;10 follicles were eligible for the PGT procedure. Each COS cycle of the FMR1-PGT group was matched with the COS cycles of partners of males carrying any type of translocation (ratio 1:3). Conditional logistic regression was performed to compare the COS outcomes. We then estimated the number of mature oocytes needed to obtain at least one healthy embryo after PGT using receiver operating characteristic curve analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Overall, in the FMR1-PGT group, the median number of retrieved and mature oocytes per cycle was 11 (interquartile range 7\u201315) and 9 (6\u201312), respectively. The COS outcomes of FMR1 premutation or full mutation female carriers were not altered compared with the matched COS cycles in partners of males carrying a balanced translocation in their karyotype. Among the 6 (4\u201310) Day 3 embryos obtained in the FMR1-PGT group, a median number of 3 (1\u20136) embryos were morphologically eligible for biopsy, leading to 1 (1\u20133) healthy embryo. A cutoff value of seven MII oocytes yielded a sensitivity of 82% and a specificity of 61% of having at least one healthy embryo, whereas a cutoff value of 10 MII oocytes led to a specificity of 85% and improved positive predictive value.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>This study is retrospective, analyzing a limited number of cycles. Moreover, the patients who were included in a fresh PGT cycle were selected on ovarian reserve parameters and show high values in ovarian reserve tests. This information could influence our conclusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>The results relate only to the target population of this study, with a correct ovarian reserve of AMH &amp;gt;1 and AFC &amp;gt;10. However, the information provided herein extends knowledge about the current state of COS for FMR1 mutation carriers in order to provide patients with proper counseling regarding the optimal number of oocytes needed to have a chance of transferring an unaffected embryo following PGT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>None.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deab214","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T19:14:02Z","timestamp":1631906042000},"page":"3003-3013","source":"Crossref","is-referenced-by-count":10,"title":["What is the threshold of mature oocytes to obtain at least one healthy transferable cleavage-stage embryo after preimplantation genetic testing for fragile X syndrome?"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-1592","authenticated-orcid":false,"given":"C","family":"Sonigo","sequence":"first","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de M\u00e9decine de la Reproduction et Pr\u00e9servation de la Fertilit\u00e9, Universit\u00e9 Paris-Saclay, Clamart, France"},{"name":"Inserm, Physiologie et Physiopathologie Endocrinienne, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5764-5382","authenticated-orcid":false,"given":"A","family":"Mayeur","sequence":"additional","affiliation":[{"name":"Laboratoire d'Histologie-Embryologie-Cytogenetique CECOS, H\u00f4pital Antoine B\u00e9cl\u00e8re, AP-HP, Universit\u00e9 Paris-Saclay, Cedex, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sadoun","sequence":"additional","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de M\u00e9decine de la Reproduction et Pr\u00e9servation de la Fertilit\u00e9, Universit\u00e9 Paris-Saclay, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pinto","sequence":"additional","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de M\u00e9decine de la Reproduction et Pr\u00e9servation de la Fertilit\u00e9, Universit\u00e9 Paris-Saclay, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Benguigui","sequence":"additional","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de M\u00e9decine de la Reproduction et Pr\u00e9servation de la Fertilit\u00e9, Universit\u00e9 Paris-Saclay, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Frydman","sequence":"additional","affiliation":[{"name":"Laboratoire d'Histologie-Embryologie-Cytogenetique CECOS, H\u00f4pital Antoine B\u00e9cl\u00e8re, AP-HP, Universit\u00e9 Paris-Saclay, Cedex, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Monnot","sequence":"additional","affiliation":[{"name":"Service de G\u00e9n\u00e9tique Mol\u00e9culaire, Groupe Hospitalier Necker-Enfants Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Benachi","sequence":"additional","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de Gyn\u00e9cologie Obst\u00e9trique, Universit\u00e9 Paris-Saclay, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Steffann","sequence":"additional","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris-Sorbonne Paris Cit\u00e9, INSERM UMR1163, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1549-1802","authenticated-orcid":false,"given":"M","family":"Grynberg","sequence":"additional","affiliation":[{"name":"Assistance Publique Hopitaux de Paris, Hopital B\u00e9cl\u00e8re, Service de M\u00e9decine de la Reproduction et Pr\u00e9servation de la Fertilit\u00e9, Universit\u00e9 Paris-Saclay, Clamart, France"},{"name":"BFA- Unit\u00e9 de Biologie Fonctionnelle et Adaptative, UMR 8251, CNRS, ERL U1133, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"2021111806384938600_deab214-B1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B","article-title":"Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study\u2013preliminary data","volume":"83","author":"Allingham-Hawkins","year":"1999","journal-title":"Am J Med Genet"},{"key":"2021111806384938600_deab214-B2","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2021111806384938600_deab214-B3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/humrep\/dex090","article-title":"The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal","volume":"32","author":"Avraham","year":"2017","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B4","doi-asserted-by":"crossref","first-page":"100055","DOI":"10.1016\/j.eurox.2019.100055","article-title":"Live birth rate is associated with oocyte yield and number of biopsied and suitable blastocysts to transfer in preimplantation genetic testing (PGT) cycles for monogenic disorders and chromosomal structural rearrangements","volume":"4","author":"Ben-Nagi","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"2021111806384938600_deab214-B5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.fertnstert.2009.04.047","article-title":"The effect of CGG repeat number on ovarian response among fragile X premutation carriers undergoing preimplantation genetic diagnosis","volume":"94","author":"Bibi","year":"2010","journal-title":"Fertil Steril"},{"key":"2021111806384938600_deab214-B6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/molehr\/gal069","article-title":"Multiple displacement amplification improves PGD for fragile X syndrome","volume":"12","author":"Burlet","year":"2006","journal-title":"Mol Hum Reprod"},{"key":"2021111806384938600_deab214-B151","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.fertnstert.2015.11.027","article-title":"Oocyte vitrification as an efficient option for elective fertility preservation","volume":"105","author":"Cobo","year":"2016","journal-title":"Fertil Steril"},{"key":"2021111806384938600_deab214-B7","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1093\/humrep\/dey321","article-title":"Elective and onco-fertility preservation: factors related to IVF outcomes","volume":"33","author":"Cobo","year":"2018","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/oxfordjournals.humrep.a138540","article-title":"Optimal preparation of preimplantation embryo interphase nuclei for analysis by fluorescence in-situ hybridization","volume":"9","author":"Coonen","year":"1994","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B9","doi-asserted-by":"crossref","first-page":"e105121","DOI":"10.1371\/journal.pone.0105121","article-title":"Elevated levels of FMR1 mRNA in granulosa cells are associated with low ovarian reserve in FMR1 premutation carriers","volume":"9","author":"Elizur","year":"2014","journal-title":"PLoS One"},{"key":"2021111806384938600_deab214-B10","first-page":"965839","article-title":"Clinical and technical overview of preimplantation genetic diagnosis for fragile X syndrome: experience at the University Hospital Virgen del Rocio in Spain","volume":"2015","author":"Fern\u00e1ndez","year":"2015","journal-title":"Biomed Res Int"},{"key":"2021111806384938600_deab214-B11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10815-020-01701-0","article-title":"Does the presence of AGG interruptions within the CGG repeat tract have a protective effect on the fertility phenotype of female FMR1 premutation carriers?","volume":"37","author":"Friedman-Gohas","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"2021111806384938600_deab214-B12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/0092-8674(91)90283-5","article-title":"Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox","volume":"67","author":"Fu","year":"1991","journal-title":"Cell"},{"key":"2021111806384938600_deab214-B13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/humrep\/deq361","article-title":"Serum anti-M\u00fcllerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation","volume":"26","author":"Genro","year":"2011","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10815-018-1293-3","article-title":"Preimplantation genetic diagnosis versus prenatal diagnosis-decision-making among pregnant FMR1 premutation carriers","volume":"35","author":"Haham","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"2021111806384938600_deab214-B15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/GME.0000000000000658","article-title":"Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI)","volume":"23","author":"Hipp","year":"2016","journal-title":"Menopause"},{"key":"2021111806384938600_deab214-B16","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ajmg.a.36511","article-title":"Epidemiology of fragile X syndrome: a systematic review and meta-analysis","volume":"164A","author":"Hunter","year":"2014","journal-title":"Am J Med Genet A"},{"key":"2021111806384938600_deab214-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000455849","article-title":"Impact of FMR1 pre-mutation status on blastocyst development in patients undergoing pre-implantation genetic diagnosis","volume":"83","author":"Hutchinson","year":"2018","journal-title":"Gynecol Obstet Invest"},{"key":"2021111806384938600_deab214-B18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.fertnstert.2020.10.051","article-title":"Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity","volume":"115","author":"Jaswa","year":"2021","journal-title":"Fertil Steril"},{"key":"2021111806384938600_deab214-B19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-med-061109-134644","article-title":"Toward fulfilling the promise of molecular medicine in fragile X syndrome","volume":"62","author":"Krueger","year":"2011","journal-title":"Annu Rev Med"},{"key":"2021111806384938600_deab214-B20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10815-021-02067-7","article-title":"Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI)","volume":"38","author":"La Marca","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"2021111806384938600_deab214-B21","first-page":"231","article-title":"A marker X chromosome","volume":"21","author":"Lubs","year":"1969","journal-title":"Am J Hum Genet"},{"key":"2021111806384938600_deab214-B22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.rbmo.2020.01.025","article-title":"Does the prognosis after PGT for structural rearrangement differ between female and male translocation carriers?","volume":"40","author":"Mayeur","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2021111806384938600_deab214-B23","author":"NCSS 2021 Statistical Software","year":"2021"},{"key":"2021111806384938600_deab214-B24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/biom11020296","article-title":"DNA methylation, mechanisms of FMR1 inactivation and therapeutic perspectives for fragile X syndrome","volume":"11","author":"Nobile","year":"2021","journal-title":"Biomolecules"},{"key":"2021111806384938600_deab214-B25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/gim.2014.106","article-title":"Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers","volume":"17","author":"Nolin","year":"2015","journal-title":"Genet Med"},{"key":"2021111806384938600_deab214-B26","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1093\/humrep\/17.11.2807","article-title":"Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible","volume":"17","author":"Platteau","year":"2002","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10815-020-01809-3","article-title":"Are ovarian response and pregnancy rates similar in selected FMR1 premutated and mutated patients undergoing preimplantation genetic testing?","volume":"37","author":"Ranisavljevic","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"2021111806384938600_deab214-B28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/pd.2179","article-title":"Preimplantation genetic diagnosis for fragile X syndrome: is there increased transmission of abnormal FMR1 alleles among female heterozygotes?","volume":"29","author":"Reches","year":"2009","journal-title":"Prenat Diagn"},{"key":"2021111806384938600_deab214-B29","first-page":"19","article-title":"Psychological Impact of Abortion due to Fetal Anomaly: A Review of Published Research","volume":"32","author":"Sullivan","year":"2017","journal-title":"Issues Law Med"},{"key":"2021111806384938600_deab214-B30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0031-1280915","article-title":"FMR1 and the continuum of primary ovarian insufficiency","volume":"29","author":"Sullivan","year":"2011","journal-title":"Semin Reprod Med"},{"key":"2021111806384938600_deab214-B31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4161\/rna.1.2.1035","article-title":"FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor\/ataxia syndrome (FXTAS)","volume":"1","author":"Tassone","year":"2004","journal-title":"RNA Biol"},{"key":"2021111806384938600_deab214-B32","doi-asserted-by":"crossref","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"The Eshre Guideline Group on Ovarian Stimulation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2021111806384938600_deab214-B33","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1093\/humrep\/deq203","article-title":"PGD for fragile X syndrome: ovarian function is the main determinant of success","volume":"25","author":"Tsafrir","year":"2010","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B34","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/humrep\/13.11.3169","article-title":"Successful preimplantation genetic diagnosis is related to the number of available cumulus-oocyte complexes","volume":"13","author":"Vandervorst","year":"1998","journal-title":"Hum Reprod"},{"key":"2021111806384938600_deab214-B35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fgene.2014.00300","article-title":"Health and reproductive experiences of women with an FMR1 premutation with and without fragile X premature ovarian insufficiency","volume":"5","author":"Wheeler","year":"2014","journal-title":"Front Genet"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/36\/11\/3003\/41165105\/deab214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/36\/11\/3003\/41165105\/deab214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T09:31:44Z","timestamp":1637227904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/11\/3003\/6375575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,26]]},"published-print":{"date-parts":[[2021,10,18]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab214","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,9,26]]}}}